药物遗传学可能解释新生儿多巴酚丁胺药效学个体差异
AIMS: To determine whether the known single nucleotide polymorphisms in adrenoreceptor associated genes affect the haemodynamic response to dobutamine in critically ill neonates.…
要点
- β1-AR Arg389Gly中G等位基因携带者多巴酚丁胺增加心率更明显。
- GNAS c.393C>T中T等位基因携带者多巴酚丁胺增加左、右心室输出量。
- 药物遗传学可能部分解释新生儿多巴酚丁胺药效学个体差异。
核心结论
- 在危重新生儿中,β1-AR Arg389Gly和GNAS c.393C>T多态性可能影响出生后最初数小时至数天多巴酚丁胺的血流动力学反应。
研究设计与样本
- 检测β1-和β2-肾上腺素受体基因及GNAS基因中已知单核苷酸多态性等位基因。
- 采用线性混合效应模型描述遗传多态性对多巴酚丁胺治疗期间心率、左心室输出量和右心室输出量的影响。
临床怎么用
- 临床使用多巴酚丁胺时,可关注β1-AR Arg389Gly和GNAS c.393C>T多态性以预测血流动力学反应差异。
- 对携带β1-AR Gly等位基因或GNAS T等位基因的新生儿,多巴酚丁胺的心率和心室输出量反应可能更明显。
- 上述基因型检测结果需结合临床状态综合解读,尚不能作为常规剂量调整的唯一依据。
局限性
- 研究仅纳入已知单核苷酸多态性,未覆盖其他可能影响药效的遗传变异。
- 研究为观察性药代动力学-药效学研究,遗传因素与临床结局的因果关系未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To determine whether the known single nucleotide polymorphisms in adrenoreceptor associated genes affect the haemodynamic response to dobutamine in critically ill neonates. METHODS: Alleles in the known genetic single nucleotide polymorphisms in β1- and β2-adrenoceptor (AR) genes and Gs protein α-subunit gene (GNAS) possibly affecting inotropic effect were identified in patients of neonatal dobutamine pharmacokinetic-pharmacodynamic study. Linear mixed-effect models were used to describe the effect of genetic polymorphisms to heart rate (HR), left ventricular output (LVO) and right ventricular output (RVO) during dobutamine treatment. RESULTS: Twenty-six neonates (5 term, 21 preterm) were studied. Dobutamine plasma concentration and exposure time respective HR (adjusted to gestational age) is dependent on β1-AR Arg389Gly polymorphism so that in G/G (Gly) homozygotes and G/C heterozygotes dobutamine increases HR more than in C/C (Arg) homozygotes, with parameter estimate (95% CI) of 38.3 (15.8-60.7) beats/min per AUC of 100 μg L-1 h, P = .0008. LVO (adjusted to antenatal glucocorticoid administration and illness severity) and RVO (adjusted to gestational age and illness severity) is dependent on GNAS c.393C > T polymorphism so that in T/T homozygotes and C/T heterozygotes but not in C/C homozygotes LVO and RVO increase with dobutamine treatment, 24.5 (6.2-42.9) mL kg-1 min-1 per AUC of 100 μg L-1 h, P = .0095 and 33.2 (12.1-54.3) mL kg-1 min-1 per AUC of 100 μg L-1 h, P = .0025, respectively. CONCLUSION: In critically ill neonates, β1-AR Arg389Gly and GNAS c.393C > T polymorphisms may play a role in the haemodynamic response to dobutamine during the first hours and days of life.
引用
- Hallik M, Soeorg H, Kahre T, et al. Pharmacogenetics may explain part of the interindividual variability of dobutamine pharmacodynamics in neonates. Br J Clin Pharmacol. 2022. PMID: 35437830. doi:10.1111/bcp.15357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。